Health
Opaganib shows promise in preventing ARDS-induced thrombosis – Drug Target Review
Opaganib reduced blood clot length and weight in a preclinical model of Acute Respiratory Distress Syndrome (ARDS).
Posted: 16 December 2020 | Hannah Balfour (Drug Target Review) | No comments yet
Opaganib reduced blood clot length and weight in a preclinical model of Acute Respiratory Distress Syndrome (ARDS).
Opaganib (Yeliva®), a novel, orally administered sphingosine kinase 2 (SK2) selective inhibitor, (administered at 250mg/kg,) reduced thrombosis in a preclinical model of Acute Respiratory Distress Syndrome (ARDS).
According to the researchers, their findings suggest opaganib may be of benefit to patients…
-
Noosa News22 hours agoHow Lily Steele-Park took her rapist to court and won
-
Noosa News23 hours agoE-biker charged with riding dangerously, assaulting cop
-
General21 hours agoBrick portico a relic of ‘prestigious’ Horton College in northern midlands
-
Business16 hours agoWhy Vault Minerals, Droneshield, Westgold Resources shares are climbing higher today